

Applicants submit herewith a Supplemental Sequence Listing Submission responsive to the Notice to Comply with Sequence Disclosures.

Applicants also submit herewith certified copies of the priority applications of the present case, i.e. European applications 97116863.8, 97122471.2 and 98104216.1.

Claims 1 and 2 were objected to under 37 CFR 1.821(d) for not reciting SEQ ID NOS. in the claims.

The new claims recite SEQ ID NOS. as appropriate. Accordingly, it is believed the objection should be withdrawn.

Claims 4, 9 and 12 were objected to under 37 CFR 1.75 (c) with respect to form of multiple dependencies.

The claims pending herein have proper multiple dependent form. Thus, the objection is believed to be obviated.

Claims 1-4 and 9 were rejected under 35 U.S.C. 101 on grounds that those claims do not distinguish products of nature. The rejection is traversed.

The claims recite a truncated material. Such a material is not subject to rejection under Section 101.

ANTHEUS

and therefore does not constitute statutory subject matter.

Respectfully, Section 101 does not require differences in characteristics or utility from natural material.

In view thereof, withdrawal of the rejection is requested.

Claims 1-2, 4, 9 and 12 were rejected under 35 U.S.C. 112, second paragraph for formalities-type matters.

It is believed the amendments made herein obviate the rejection.

Specifically, it is believed objection to recitation of "residues 1, 1-2, 1-3, or 1-4 of the naturally occurring RANTES" and "naturally-occurring" is obviated by the addition to SEQ ID NOS. The new claims also have proper antecedent basis.

Claims 1-3, 9 and 12 were rejected under 35 U.S.C. 102 over Oravec et al. (J. Exp. Med. 1997; 186:1865-1872).

The cited document has a date after Applicants' priority date. As indicated above, certified copies of the priority documents are enclosed herewith.

Claims 1-4 and 9 were rejected under 35 U.S.C. 102 over Noso et al. (J. Immunol. 1996; 155: 1946-1953).

Noso et al. does not teach Applicants' claimed subject matter in any manner sufficient to sustain the instant rejection.

material. Notably, Noso et al. does not report any anti-inflammatory activity.

disclosed in the present application, further indicating Noso et al. does not disclose Applicants' claimed subject matter.

Claims 1-2, 9 and 12 were rejected under 35 U.S.C. 102 over Gong et al. (J. Biol. Chem. 1996; 271: 10521-10527). Claims 1-4, 9 and 12 also were rejected under 35 U.S.C. 103 over Gong et al.

Gong et al. is similarly deficient.

Gong et al. does not teach or suggest Applicants' claimed subject matter in any manner sufficient to sustain the instant rejection.

Further, Gong et al. provides no disclosure of any antagonistic activity of a truncated material as disclosed in the present application

Claims 1-2, 4, 9 and 12 were rejected under 35 U.S.C. 102(e) over Rollin et al. (U.S. Patent 5,739,103).

The entire thrust of the Rollins documents is directed to certain **MCP-1** compounds, and clearly not to truncated RANTES compounds lacking NH₂-terminal amino acids. See columns 4 through 11 of Rollins et al. All the examples of Rollins et al. are limited to MCP-1.

Nowhere does Rollin et al. report particular manipulation or other use of RANTES compounds of any type.


P. Proost et al.
U.S.S.N. 09/537,858
Page 6

1-4 of naturally-occurring RANTES and having chemokine antagonistic activity, as Applicants disclose and claim.

In view thereof, the rejection should be withdrawn. See *In re Marshall*, 198 USPQ 344, 346 (CCPA 1978) ("[r]ejections under 35 U.S.C. 102 are proper only when the claimed subject matter is identically disclosed or described in the prior art.>").

It is believed the application is in condition for immediate allowance, which action is earnestly solicited.

Respectfully submitted,


Christine C. O'Day (Reg. No. 38,256)
Peter F. Corless (Reg. 33,860)
EDWARDS & ANGELL, LLP
Dike, Bronstein, Roberts & Cushman IP Group
P.O. Box 9169
Boston, Massachusetts 02209
(617) 439-4444

VERSION MARKED TO SHOW CHANGES

IN THE CLAIMS:

Non-elected claims 1-14 have been cancelled without prejudice.

The following new claims were added.

15. An isolated amino-terminally truncated RANTES lacking NH₂-terminal amino acids corresponding to amino acid residues 1, 1-2, 1-3 or 1-4 of naturally-occurring RANTES (SEQ ID NO. 2) and having chemokine antagonistic activity.

16. The isolated RANTES of claim 15, wherein the purified RANTES lacks NH₂-terminal amino acids corresponding to amino acid residues 1-2 of naturally-occurring RANTES (SEQ ID NO. 2).

17. The isolated RANTES of claim 15, wherein the purified RANTES has the amino acid sequence of SEQ ID NO: 3.

18. The isolated RANTES of claim 15, wherein the purified RANTES lacks NH₂-terminal amino acids corresponding to amino acid residue 1 of naturally-occurring RANTES (SEQ ID NO. 2).

19. The isolated RANTES of claim 15, wherein the purified RANTES lacks NH₂-terminal amino acids corresponding to amino acid residues 1-3 of naturally-occurring RANTES (SEQ ID NO. 2).

20. The isolated RANTES of claim 15, wherein the purified RANTES lacks NH₂-terminal amino acids corresponding to amino acid residues 1-4 of naturally-occurring RANTES (SEQ ID NO. 2).

21. The isolated RANTES of any one of claims 15 through 20 wherein the truncated RANTES is in glycosylated form.

22. A pharmaceutical composition comprising a truncated RANTES of any one of claims 15 through 20 and one or more pharmaceutically acceptable carriers and/or excipients.

23. A pharmaceutical composition comprising a truncated RANTES of claim 21 and one or more pharmaceutically acceptable carriers and/or excipients.